JP2013541576A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013541576A5 JP2013541576A5 JP2013537158A JP2013537158A JP2013541576A5 JP 2013541576 A5 JP2013541576 A5 JP 2013541576A5 JP 2013537158 A JP2013537158 A JP 2013537158A JP 2013537158 A JP2013537158 A JP 2013537158A JP 2013541576 A5 JP2013541576 A5 JP 2013541576A5
- Authority
- JP
- Japan
- Prior art keywords
- insulin
- present
- age
- treatment
- symptoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010022095 Injection Site reaction Diseases 0.000 description 1
- 108010089308 Insulin Detemir Proteins 0.000 description 1
- 108010057186 Insulin Glargine Proteins 0.000 description 1
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 208000030962 Subcutaneous tissue disease Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960002869 insulin glargine Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10190303.7 | 2010-11-08 | ||
| EP10190303 | 2010-11-08 | ||
| EP11151059.0 | 2011-01-17 | ||
| EP11151059 | 2011-01-17 | ||
| PCT/EP2011/069532 WO2012062698A1 (en) | 2010-11-08 | 2011-11-07 | Pharmaceutical composition, methods for treating and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015100121A Division JP6141907B2 (ja) | 2010-11-08 | 2015-05-15 | 医薬組成物、治療方法及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013541576A JP2013541576A (ja) | 2013-11-14 |
| JP2013541576A5 true JP2013541576A5 (enExample) | 2014-10-23 |
Family
ID=44906182
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013537158A Pending JP2013541576A (ja) | 2010-11-08 | 2011-11-07 | 医薬組成物、治療方法及びその使用 |
| JP2015100121A Active JP6141907B2 (ja) | 2010-11-08 | 2015-05-15 | 医薬組成物、治療方法及びその使用 |
| JP2017019822A Active JP6515121B2 (ja) | 2010-11-08 | 2017-02-06 | 医薬組成物、治療方法及びその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015100121A Active JP6141907B2 (ja) | 2010-11-08 | 2015-05-15 | 医薬組成物、治療方法及びその使用 |
| JP2017019822A Active JP6515121B2 (ja) | 2010-11-08 | 2017-02-06 | 医薬組成物、治療方法及びその使用 |
Country Status (31)
| Country | Link |
|---|---|
| US (6) | US20120283169A1 (enExample) |
| EP (2) | EP2637648A1 (enExample) |
| JP (3) | JP2013541576A (enExample) |
| KR (3) | KR20130125365A (enExample) |
| CN (2) | CN103282030A (enExample) |
| AP (1) | AP2013006813A0 (enExample) |
| AR (1) | AR083787A1 (enExample) |
| AU (1) | AU2011328231B2 (enExample) |
| BR (1) | BR112013011968A2 (enExample) |
| CA (1) | CA2813661C (enExample) |
| CL (1) | CL2013001104A1 (enExample) |
| CO (1) | CO6781465A2 (enExample) |
| DK (1) | DK3539540T3 (enExample) |
| EA (1) | EA026712B1 (enExample) |
| EC (1) | ECSP13012661A (enExample) |
| ES (1) | ES3012504T3 (enExample) |
| FI (1) | FI3539540T3 (enExample) |
| HR (1) | HRP20250096T1 (enExample) |
| HU (1) | HUE070541T2 (enExample) |
| IL (1) | IL225597A0 (enExample) |
| LT (1) | LT3539540T (enExample) |
| MA (1) | MA34640B1 (enExample) |
| MX (2) | MX356491B (enExample) |
| NZ (1) | NZ608829A (enExample) |
| PE (1) | PE20140244A1 (enExample) |
| PH (2) | PH12013500809A1 (enExample) |
| PL (1) | PL3539540T3 (enExample) |
| RS (1) | RS66479B1 (enExample) |
| SG (1) | SG189249A1 (enExample) |
| SI (1) | SI3539540T1 (enExample) |
| WO (1) | WO2012062698A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
| PE20080697A1 (es) | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
| PE20090938A1 (es) | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
| EP2395983B1 (en) | 2009-02-13 | 2020-04-08 | Boehringer Ingelheim International GmbH | Pharmaceutical composition comprisng a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof |
| SI2486029T1 (sl) | 2009-09-30 | 2015-10-30 | Boehringer Ingelheim International Gmbh | Postopki za pripravo z glukopiranozilom substituiranih benzil-benzenskih derivatov |
| EP2483286B1 (en) | 2009-09-30 | 2016-07-13 | Boehringer Ingelheim International GmbH | Method for the preparation of a crystalline form of 1-chloro-4-(beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene |
| US10610489B2 (en) | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
| US20120283169A1 (en) | 2010-11-08 | 2012-11-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| AR085689A1 (es) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| PL2981269T3 (pl) | 2013-04-04 | 2024-02-05 | Boehringer Ingelheim Vetmedica Gmbh | Leczenie zaburzeń metabolicznych u zwierząt koniowatych |
| CA2812016A1 (en) | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US20140303097A1 (en) * | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| TR201901110T4 (tr) | 2013-04-05 | 2019-02-21 | Boehringer Ingelheim Int | Empagliflozinin terapötik kullanımları. |
| CA2812519A1 (en) | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CN113181161A (zh) | 2013-04-18 | 2021-07-30 | 勃林格殷格翰国际有限公司 | 药物组合物、治疗方法及其用途 |
| LT3862003T (lt) * | 2013-12-17 | 2023-12-27 | Boehringer Ingelheim Vetmedica Gmbh | Sglt-2 inhibitorius, skirtas naudoti taikant medžagų apykaitos sutrikimo gydymą kačių šeimos gyvūnams |
| EA032558B1 (ru) | 2014-01-23 | 2019-06-28 | Бёрингер Ингельхайм Ветмедика Гмбх | Лечение метаболических расстройств у представителей собачьих |
| MX376911B (es) | 2014-04-01 | 2025-03-07 | Boehringer Ingelheim Vetmedica Gmbh | Inhibidores de sglt2 para usarse en el tratamiento de trastornos metabolicos en animales equinos. |
| EP3197429B1 (en) | 2014-09-25 | 2024-05-22 | Boehringer Ingelheim Vetmedica GmbH | Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals |
| CN104473920A (zh) * | 2014-12-20 | 2015-04-01 | 长沙佰顺生物科技有限公司 | 一种用于治疗2型糖尿病的复方制剂及其制备方法 |
| EP3341024B1 (en) | 2015-08-27 | 2024-10-09 | Boehringer Ingelheim Vetmedica GmbH | Liquid pharmaceutical compositions comprising sglt-2 inhibitors |
| MA46742A (fr) | 2016-11-10 | 2019-09-18 | Boehringer Ingelheim Int | Composition pharmaceutique, méthodes de traitement et leurs utilisations |
| CN110092768A (zh) * | 2018-04-23 | 2019-08-06 | 中国科学院成都生物研究所 | 包含钠-葡萄糖协同转运蛋白1抑制剂的组合物及使用方法 |
| KR20220038339A (ko) * | 2019-07-23 | 2022-03-28 | 노파르티스 아게 | Sglt 억제제, 예를 들어 sglt 1/2 억제제를 포함하는 치료 |
| CN110327355B (zh) * | 2019-08-12 | 2021-06-04 | 浙江养生堂天然药物研究所有限公司 | 包含柠檬苦素类化合物和sglt-2抑制剂的组合产品 |
| EP4025197A4 (en) * | 2019-09-04 | 2023-09-13 | The Regents Of The University Of Michigan | SGLT INHIBITORS AND THEIR USES |
| US20210093698A1 (en) * | 2019-09-13 | 2021-04-01 | Sanofi | Treatment of type 2 diabetes mellitus |
| WO2025007870A1 (zh) * | 2023-07-04 | 2025-01-09 | 连云港市瓦尔生物医药科技有限公司 | 一种控制血糖的药物组合试剂盒 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU229581B1 (en) | 1999-08-31 | 2014-02-28 | Kissei Pharmaceutical | Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof |
| PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| CA2429833A1 (en) | 2000-11-30 | 2002-06-06 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof |
| WO2002053573A1 (en) | 2000-12-28 | 2002-07-11 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxypyrazole derivatives and use thereof in medicines |
| AU2003211543B2 (en) | 2002-03-22 | 2009-03-12 | Kissei Pharmaceutical Co., Ltd. | Crystals of glucopyranosyloxybenzyl benzene derivative |
| DE10231370B4 (de) | 2002-07-11 | 2006-04-06 | Sanofi-Aventis Deutschland Gmbh | Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
| ES2363941T3 (es) | 2003-03-14 | 2011-08-19 | Astellas Pharma Inc. | Derivados de c-glucósido para el tratamiento de diabetes. |
| ES2649737T5 (es) | 2003-08-01 | 2021-07-07 | Mitsubishi Tanabe Pharma Corp | Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio |
| DE102004012676A1 (de) * | 2004-03-16 | 2005-10-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Glucopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| CN103030617A (zh) | 2004-03-16 | 2013-04-10 | 贝林格尔.英格海姆国际有限公司 | 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法 |
| AR051446A1 (es) * | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) |
| WO2006064033A2 (en) | 2004-12-16 | 2006-06-22 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
| US7723309B2 (en) | 2005-05-03 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
| UA91546C2 (uk) | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ |
| US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
| ATE484499T1 (de) | 2005-08-30 | 2010-10-15 | Boehringer Ingelheim Int | Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür |
| CA2621314A1 (en) | 2005-09-08 | 2007-03-15 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(.beta.-d-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments |
| AR056195A1 (es) | 2005-09-15 | 2007-09-26 | Boehringer Ingelheim Int | Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos |
| US7745414B2 (en) | 2006-02-15 | 2010-06-29 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture |
| TWI370818B (en) | 2006-04-05 | 2012-08-21 | Astellas Pharma Inc | Cocrystal of c-glycoside derivative and l-proline |
| PE20080697A1 (es) | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
| WO2007140191A2 (en) | 2006-05-23 | 2007-12-06 | Theracos, Inc. | Glucose transport inhibitors and methods of use |
| US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
| DE102006031962A1 (de) | 2006-07-11 | 2008-01-17 | Sanofi-Aventis Deutschland Gmbh | Amidiertes Insulin Glargin |
| TWI403516B (zh) | 2006-07-27 | 2013-08-01 | Chugai Pharmaceutical Co Ltd | To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes |
| CA2656847A1 (en) | 2006-08-15 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture |
| CA2667550A1 (en) | 2006-10-27 | 2008-05-02 | Boehringer Ingelheim International Gmbh | Crystalline form of 4-(.beta.-d-glucopyranos-1-yl)-1-methyl-2-[4-((s)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
| US7879806B2 (en) | 2006-11-06 | 2011-02-01 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzonitrile derivates, medicaments containing such compounds, their use and process for their manufacture |
| WO2008055940A2 (en) * | 2006-11-09 | 2008-05-15 | Boehringer Ingelheim International Gmbh | Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions |
| UY30730A1 (es) | 2006-12-04 | 2008-07-03 | Mitsubishi Tanabe Pharma Corp | Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno |
| PE20090185A1 (es) * | 2007-03-22 | 2009-02-28 | Bristol Myers Squibb Co | Formulaciones farmaceuticas que contienen un inhibidor sglt2 |
| CA2699285C (en) | 2007-09-10 | 2016-12-13 | Ahmed F. Abdel-Magid | Process for the preparation of compounds useful as inhibitors of sodium-dependent glucose transporter (sglt) |
| AU2009203810B2 (en) | 2008-01-09 | 2013-07-25 | Sanofi-Aventis Deutschland Gmbh | Novel insulin derivatives having an extremely delayed time-action profile |
| NZ586590A (en) | 2008-01-09 | 2012-06-29 | Sanofi Aventis Deutschland | Insulin analogues or derivatives having an extremely delayed time-action profile |
| CN101503399B (zh) * | 2008-02-04 | 2012-06-27 | 白鹭医药技术（上海）有限公司 | C-芳基葡萄糖苷sglt2抑制剂 |
| TWI451876B (zh) | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
| KR20110118668A (ko) | 2009-02-13 | 2011-10-31 | 베링거 인겔하임 인터내셔날 게엠베하 | １형 당뇨병, ２형 당뇨병, 내당능 장애 또는 고혈당증을 치료하기 위한 ｓｇｌｔ２ 억제제 |
| UY32427A (es) | 2009-02-13 | 2010-09-30 | Boheringer Ingelheim Internat Gmbh | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma |
| KR20110126614A (ko) | 2009-02-13 | 2011-11-23 | 베링거 인겔하임 인터내셔날 게엠베하 | 글루코피라노실 디페닐메탄 유도체를 포함하는 약제학적 조성물, 이들의 약제학적 용량형, 이들의 제조방법 및 환자에서의 개선된 당 조절을 위한 이들의 용도 |
| CN105477639A (zh) * | 2009-04-16 | 2016-04-13 | 大正制药株式会社 | 药物组合物 |
| JP2012528170A (ja) * | 2009-05-27 | 2012-11-12 | ブリストル−マイヤーズ スクイブ カンパニー | 別の抗糖尿病薬を用いた先の治療に抵抗性を有する２型糖尿病患者をｓｇｌｔ２阻害剤およびその組成物を用いて治療する方法 |
| JP2013523681A (ja) * | 2010-03-30 | 2013-06-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｇｌｔ２インヒビター及びｐｐａｒ−ガンマアゴニストを含む医薬組成物並びにその使用 |
| US20120283169A1 (en) * | 2010-11-08 | 2012-11-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| JP5876170B2 (ja) * | 2015-01-13 | 2016-03-02 | 株式会社平和 | 遊技機 |
-
2011
- 2011-11-02 US US13/287,216 patent/US20120283169A1/en not_active Abandoned
- 2011-11-07 PL PL19163940.0T patent/PL3539540T3/pl unknown
- 2011-11-07 HR HRP20250096TT patent/HRP20250096T1/hr unknown
- 2011-11-07 WO PCT/EP2011/069532 patent/WO2012062698A1/en not_active Ceased
- 2011-11-07 NZ NZ608829A patent/NZ608829A/en unknown
- 2011-11-07 AP AP2013006813A patent/AP2013006813A0/xx unknown
- 2011-11-07 BR BR112013011968A patent/BR112013011968A2/pt not_active IP Right Cessation
- 2011-11-07 JP JP2013537158A patent/JP2013541576A/ja active Pending
- 2011-11-07 LT LTEP19163940.0T patent/LT3539540T/lt unknown
- 2011-11-07 MX MX2013005095A patent/MX356491B/es active IP Right Grant
- 2011-11-07 CN CN201180064091XA patent/CN103282030A/zh active Pending
- 2011-11-07 KR KR1020137011966A patent/KR20130125365A/ko not_active Ceased
- 2011-11-07 KR KR1020187022985A patent/KR102051285B1/ko active Active
- 2011-11-07 DK DK19163940.0T patent/DK3539540T3/da active
- 2011-11-07 EA EA201300550A patent/EA026712B1/ru not_active IP Right Cessation
- 2011-11-07 PH PH1/2013/500809A patent/PH12013500809A1/en unknown
- 2011-11-07 CA CA2813661A patent/CA2813661C/en active Active
- 2011-11-07 MX MX2018006655A patent/MX374694B/es unknown
- 2011-11-07 AR ARP110104151A patent/AR083787A1/es unknown
- 2011-11-07 KR KR1020197034873A patent/KR102232451B1/ko active Active
- 2011-11-07 RS RS20250115A patent/RS66479B1/sr unknown
- 2011-11-07 HU HUE19163940A patent/HUE070541T2/hu unknown
- 2011-11-07 SG SG2013024849A patent/SG189249A1/en unknown
- 2011-11-07 EP EP11778916.4A patent/EP2637648A1/en not_active Withdrawn
- 2011-11-07 CN CN201610579791.7A patent/CN106177957A/zh active Pending
- 2011-11-07 ES ES19163940T patent/ES3012504T3/es active Active
- 2011-11-07 FI FIEP19163940.0T patent/FI3539540T3/fi active
- 2011-11-07 EP EP19163940.0A patent/EP3539540B1/en active Active
- 2011-11-07 AU AU2011328231A patent/AU2011328231B2/en active Active
- 2011-11-07 SI SI201132125T patent/SI3539540T1/sl unknown
- 2011-11-07 PE PE2013000955A patent/PE20140244A1/es not_active Application Discontinuation
-
2013
- 2013-04-07 IL IL225597A patent/IL225597A0/en unknown
- 2013-04-22 CL CL2013001104A patent/CL2013001104A1/es unknown
- 2013-05-02 MA MA35865A patent/MA34640B1/fr unknown
- 2013-05-08 CO CO13115446A patent/CO6781465A2/es not_active Application Discontinuation
- 2013-06-04 EC ECSP13012661 patent/ECSP13012661A/es unknown
-
2014
- 2014-01-17 US US14/157,678 patent/US20140256624A1/en not_active Abandoned
-
2015
- 2015-05-15 JP JP2015100121A patent/JP6141907B2/ja active Active
-
2017
- 2017-02-06 JP JP2017019822A patent/JP6515121B2/ja active Active
-
2018
- 2018-03-08 US US15/915,396 patent/US20180193427A1/en not_active Abandoned
- 2018-04-06 PH PH12018500767A patent/PH12018500767A1/en unknown
-
2020
- 2020-03-18 US US16/822,360 patent/US20200397867A1/en not_active Abandoned
-
2021
- 2021-08-12 US US17/400,221 patent/US20220152159A1/en not_active Abandoned
-
2024
- 2024-06-18 US US18/746,567 patent/US20240335514A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013541576A5 (enExample) | ||
| Kann et al. | Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride | |
| MX2011007371A (es) | Metodo para tratar la hiperglucemia con la molecula. | |
| JP2008534622A5 (enExample) | ||
| Mokta et al. | Insulin lipodystrophy and lipohypertrophy | |
| Enginyurt et al. | The role of pure honey in the treatment of diabetes mellitus | |
| Pickup | Insulin pumps | |
| Joshi et al. | Designer insulins regimens in clinical practice-pilot multicenter indian study | |
| Belaynew et al. | Nutritional status of adults living with HIV/AIDS at the University of Gondar Referral Hospital, Northwest Ethiopia | |
| Chakraborty et al. | Distant site lipoatrophy: a rare complication of subcutaneous insulin therapy | |
| Ghosal et al. | Insulin glargine versus insulin degludec in patients failing on oral therapy in type 2 diabetes: a retrospective real world comparative data from India | |
| Kara et al. | Efficacy and safety of sirolimus (mTOR inhibitor) in two patients with diazoxide-unresponsive hyperinsulinemic hypoglycemia | |
| Paul | Managing uncontrolled type 2 diabetes: role of hydroxychloroquine in therapy as AD on antidiabetic agent: a case study | |
| WANG et al. | Investigation and nursing strategy of the current status of insulin therapy in 450 children with type 1 diabetes mellitus | |
| WO2012141764A3 (en) | Pre-operative use of metabolic activation therapy | |
| Vinik | Benefits of early initiation of insulin therapy to long-term goals in type 2 diabetes mellitus | |
| Triplitt | Cardiac risk factors and hypoglycemia in an elderly patient: how good is good enough? | |
| Annabestani et al. | Insulin buccal spray (Oral-Lyn) efficacy in type 1 diabetes | |
| Hompesch et al. | Glycemic exposure is affected favorably by inhaled human insulin (Exubera) as compared with subcutaneous insulin glargine (Lantus) in patients with type 2 diabetes | |
| Tarigan et al. | Strategy of insulin intensification after basal failure for type 2 diabetes in the outpatient setting | |
| Madhuri et al. | An overview of recent developments in clinical trials of anti-diabetic drugs | |
| Cao | Diabetic ketoacidosis: case report | |
| Ridderstråle et al. | Empagliflozin (EMPA) compared with glimepiride (GLIM) as add-on to metformin (MET) for 2 years in patients with type 2 diabetes (T2DM) | |
| KK et al. | Prevalence of Diabetic Retinopathy and Associated Factors in Type 2 Diabetes in a Tertiary Care Centre in Kannur District of Kerala | |
| CN201603288U (zh) | 小儿防病治病袜子 |